Welcome!

News Feed Item

RNAi for Therapeutic Applications: Technology and Market 2014-2024

LONDON, February 20, 2014 /PRNewswire/ --

Potential of RNAi therapies - new analysis showing R&D, trends, and revenue prospects

Where are RNA interference based medicines going? For those treatments you can get new sales predictions and explore developments. You unlock that emerging medical industry. And you assess its results, trends, technologies, potentials, and opportunities.

Visiongain's new report forecasts those revenues to 2024 at overall world market, product, and national level. Discover now what's happening. You stay ahead in data, then, helping your influence. Hear about potential gains for companies pioneering those drugs.

Forecasts to 2024 and other analyses predict and explain the RNAi-based drug market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024, also with historical data, growth rates, and market shares.

Also you investigate research and development, assessing its potential. The study also gives 59 tables, 26 charts, and interviews with two companies.

Prospects for that technology - analyses showing where the money lies

The new report shows the lucrative opportunities for ribonucleic acid interference (RNAi) technologies. And you discover forecasting for both optimistic and conservative scenarios. Those analyses predict how much money the pharma industry can earn.

See how that original analysis can benefit your reputation for commercial insight.

And the following sections explain what our investigation gives to help your research, analyses, and decisions.

Sales predictions for that world market and its products

What secrets influence RNAi medicine's future? Once companies overcome technological challenges - gaining regulatory approval - patients will benefit. Discover in our report overall world revenue estimates to 2024 with discussions of trends and prospects.

Also you find individual revenue forecasts to 2024 for 11 therapeutic agents, including these:
• PF-655
• QPI-1007
• SYL040012
• ALN-RSV01
• ARC-520
• SPC3649 (Miravirsen).

There you assess advances and outlooks for those biopharmaceuticals. Hear where you could profit.

Where lie the best prospects? There you explore outlooks for sales, assessing where revenues and profits lie. Find data on gene silencing and its business potential.

For that biotechnology, our work also shows you geographical revenue predictions.

To see an exec summary of this report please email Sara Peerun on [email protected]

National markets - what outlooks to 2024 for RNAi drug revenues?

Advances in science, biotechnology and pharma expand possibilities of medicines harnessing RNAi interference. You gain feel for those technologies' revenue prospects.

So our analyses give you individual revenue forecasts to 2024 for 11 national markets:
United States (US)
Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.

There you find regions with highest revenues, demand, and potential sales growth. Our work explains. You see international prospects.

Explore, too, how RNAi technology can benefit its developers, producers, marketers, and sellers. Our work shows you, also discussing technological progress and its meaning.

Developing products - discover trends, innovations, and progress

You also investigate R&D, finding technological and commercial possibilities. Our report discusses these advances and others:
• Short or small interfering RNA (siRNA)
• Expressed/DNA-directed RNAi (ddRNAi)
• Locked nucleic acid (LNA) and short hairpin RNA (shRNA), inc. viral vectors
• microRNA (miRNA) - natural gene expression regulators
• Novel drug delivery, including nanoparticle-based systems.

And it explores applications such as these:
• Ocular disorders, inc. age-related macular degeneration (AMD) and glaucoma
• Lung conditions, inc. respiratory syncytial virus (RSV) infection
• Infectious diseases, inc. hepatitis B and C virus (HBV and HCV) infections
• Kidney disease, inc. delayed graft function (DGF)
• Cancers - advantages in oncology.

Despite difficulties, pre-clinical and clinical developments there hold strength, variety, and promise. See what's possible for big pharma and specialists in biological drugs (biologics).

And what events change that industry? Our work shows you, discussing trends and needs.

Developments, challenges, and effects influencing RNAi technologies

The report explains forces affecting that industry and market from 2014, including these:
• Reducing side effects, including adverse immune reactions
• Orphan drug designation for competitive advantages
• Personalised therapy, inc. targeting multiple cancer subtypes
• Prospects for combination therapy
• Strategic alliances, out-licensing technology, and contract manufacturing.

What happens next? There discover what the present and future hold. You examine what encourages and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on [email protected]

Analysis of companies leading that biotechnological field

From this decade, technological developments and needs of patients, doctors, and payers will encourage investments, medical advances, and sales of RNAi-based therapeutics.

And there you examine activities of many organisations, including these:
• Alnylam Pharmaceuticals
• Silence Therapeutics
• RXi Pharmaceuticals
• Quark Pharmaceuticals
• Santaris Pharma.

You find 119 organisations covered in the study. You also get interviews with authorities in that industry. Discover what participants do, say, and think.

Ways RNAi for Therapeutic Applications: Technology and Market 2014-2024 helps

In particular, our new investigation gives this knowledge to help your work:
• Revenues there to 2024 at world level and for 11 expected products - assess outlooks for approvals, production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - explore developed and developing countries for future revenues
• Activities of companies in that biomedical field - investigate technologies, R&D pipelines, drug candidates, strategies, and prospects.

Data found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore commercial outlooks.

So with our findings you're less likely to miss opportunity. Being free to choose, then, our study shows how you could save time and effort, also helping planning, decisions, and influence.

This new report is for everyone analysing emerging technologies in biopharma. For RNAi-based medicines you explore R&D trends, issues, and sales predictions. Avoid missing out, then - please order now.

To request an exec summary of this report please email Sara Peerun at           [email protected] or call Tel : +44 (0) 20 7336 6100

Or click on http://www.visiongain.com/Report/1204/RNAi-for-Therapeutic-Applications-Technology-and-Market-2014-2024

Companies Listed

Acuity Pharmaceuticals
Aegera Therapeutics
Agilent Technologies
Alcon
Allele Biotechnology
Allergan
Alnylam Pharmaceuticals
Altogen Labs
Antisense Therapeutics
Antisoma Research
Archemix Corporation
ArmaGen Technologies
Arrowhead Research Corporation
Ascletis Pharmaceuticals
AstraZeneca
Atlantic Pharmaceuticals
Atugen AG
Avecia OligoMedicines
AVI BioPharma
Bayer
Bio Synthesis
Biocon
Biogen Idec
Biomatik Corporation
Biomics Biotechnologies
Bionexus
BioSpring
Bristol-Myers Squibb
Calando Pharmaceuticals
Carnegie Institution for Science
Chinese University of Hong Kong
Cubist Pharmaceuticals
Dainippon Sumitomo Pharma
Dharmacon RNAi Technologies
Eleos
Eli Lilly
Enzo Therapeutics
Enzon Pharmaceuticals
Eurofins MWG-Biotech
Eurogentec
European Commission
European Medicines Agency (EMA)
European Union (EU)
Expression Genetics
Eyetech Pharmaceuticals
EZBiolab
Food and Drug Administration (US FDA)
Gene Link
Gene Signal International
GeneCare Research Institute
GeneDesign
Genentech
Genta Incorporated
Genzyme
Girindus America
Gradalis
GlaxoSmithKline (GSK)
Halo-Bio RNAi Therapeutics
Integrated DNA Technologies
Intradigm Corporation
Invitrogen
Isarna Therapeutics
ISIS Pharmaceuticals
Kyowa Hakko Kirin
Life Technologies
Lorus Therapeutics
Marina Biotech
Mary Crowley Cancer Research Centre
Max Planck Institute
MedImmune
Medtronic
Merck & Co.
Merz Pharmaceuticals
Nitto Denko Corporation
Novartis
NovaRx Corporation
Novosom
Noxxon Pharma
Ohio State University (OSU)
Oligoengine
OncoGenex Technologies
Ophthotech Corporation
OPKO Health
OSI Pharmaceuticals
Pfizer
Protiva Biotherapeutics
Qiagen
Quark Biotech
Quark Pharmaceuticals
Regado Biosciences
Regeneron Pharmaceuticals
Ribopharma AG
RiboTask
RXi Pharmaceuticals
Roche
SABiosciences
Samyang Corporation
Santaris Pharma
Sanofi
Shire
Sigma Aldrich
Silence Therapeutics
Sirnaomics
Sirna Therapeutics
Spanish Society for Glaucoma
Solvay Group
Suzhou Ribo Life Sciences
Sylentis
Talon Pharmaceuticals
Takeda
Targeted Genetics Corporation
Tekmira Pharmaceuticals
Teva Pharmaceuticals
The Medicines Company
Thermo Scientific
Traversa Therapeutics
University of Bayreuth
University of Massachusetts Medical School
VIRxSYS
World Health Organization (WHO)
Zeltia Group

To see an exec summary of this report please email Sara Peerun on [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
IoT is fundamentally transforming the auto industry, turning the vehicle into a hub for connected services, including safety, infotainment and usage-based insurance. Auto manufacturers – and businesses across all verticals – have built an entire ecosystem around the Connected Car, creating new customer touch points and revenue streams. In his session at @ThingsExpo, Macario Namie, Head of IoT Strategy at Cisco Jasper, will share real-world examples of how IoT transforms the car from a static p...
The vision of a connected smart home is becoming reality with the application of integrated wireless technologies in devices and appliances. The use of standardized and TCP/IP networked wireless technologies in line-powered and battery operated sensors and controls has led to the adoption of radios in the 2.4GHz band, including Wi-Fi, BT/BLE and 802.15.4 applied ZigBee and Thread. This is driving the need for robust wireless coexistence for multiple radios to ensure throughput performance and th...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the protocols that communicate data and the emerging data analy...
I’m going to cry tonight, long and hard. I’ll do so as I remember and mourn Jeremy Geelan. I knew Jeremy for almost 20 years, from the time he showed up one day at Cloud Expo’s headquarters in Bergen County, New Jersey, and went to work. The show wasn’t called Cloud Expo then, of course – it was still known as Java Edge, a pioneering event that grabbed developers, architects, and enterprise IT users alike for twice-yearly confabs. Jeremy didn’t have a job there, or even a job offer. He was s...
SYS-CON Events announced today that China Unicom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE F...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of So...
Big Data has been changing the world. IoT fuels the further transformation recently. How are Big Data and IoT related? In his session at @BigDataExpo, Tony Shan, a renowned visionary and thought leader, will explore the interplay of Big Data and IoT. He will anatomize Big Data and IoT separately in terms of what, which, why, where, when, who, how and how much. He will then analyze the relationship between IoT and Big Data, specifically the drilldown of how the 4Vs of Big Data (Volume, Variety,...
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, will discuss how VPaaS enables you to move fast, creating scalable video experiences that reach your...
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captu...
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. Big Data at Cloud Expo - to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is...